Zydus Cadila receives USFDA approval for Perphenazine

Zydus Cadila has received a final approval from US Food & Drug Administration (USFDA) to market Perphenazine tablets USP, 2 mg, 4 mg, 8 mg and 16 mg (US RLD: Trilafon tablets).

This medication is indicated for the treatment of schizophrenia and also, for the control of severe nausea and vomiting in adults. The drug will be manufactured at the group’s formulation manufacturing facility at Baddi (Himachal Pradesh).

The group now has 284 approvals and has so far, filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is a global pharmaceutical company that discovers, develops, manufactures as well as markets a broad range of healthcare therapies including small molecule drugs, biologic therapeutics and vaccines.

The stock of Zydus Cadila in today’s session was trading on a positive bias. The stock which opened gap up at Rs 302.55 as against the previous close of Rs 275.05 surged nearly 16 per cent to touch an intraday high of Rs 318.6